{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:16Z","timestamp":1790799076423,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Centre for Eye Research Australia","award":["Centre for Eye Research Australia (CERA) receives infrastructure funding from the Victorian Government."],"award-info":[{"award-number":["Centre for Eye Research Australia (CERA) receives infrastructure funding from the Victorian Government."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adalimumab is effective in treating non-infectious uveitis (NIU), but some patients develop anti-drug antibodies against adalimumab (ADA-A), which can reduce its effectiveness, resulting in active inflammation and vision loss. We sought to determine the prevalence of ADA-A in adults receiving adalimumab for NIU, and investigate factors associated with the presence of ADA-A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Body<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional study, eighty-one (46 female) consecutive adult patients receiving adalimumab for NIU at The Royal Victorian Eye and Ear Hospital, and Eye Surgery Associates in Melbourne, Australia were recruited from March 2023 to February 2024 inclusive. The median age of patients was 45 years (range 18, 87) with median disease duration of 5.3 years (range 0.4, 25.3), and median duration of adalimumab therapy of 2.3 years (range 0.2, 13.1). Panuveitis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200927, 33%) was the commonest anatomical form of uveitis treated, and most patients had bilateral uveitis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200973, 90%). The most common diagnoses were presumed idiopathic uveitis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200927, 33%) and sarcoidosis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200913, 16%). Most patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200950, 62%) were concurrently treated with conventional immunosuppression, most commonly using methotrexate (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200932, 40%). ADA-A were present in 5\/81 patients (6.2%, 95%CI 2.7, 13.6), and their presence was associated with higher Body Mass Index [median 34.9\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (IQR 32.5, 38.0) vs. 28.4\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (IQR 24.4, 31.9),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010], higher C-reactive protein [median 7.4\u00a0mg\/L (IQR 5.5, 7.9) vs. 2.0\u00a0mg\/L (IQR 0.0, 6.0),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030], lower patient-reported health [median 5\/10 (IQR 5, 6) vs. 8\/10 (IQR 6, 8),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024], and lower serum adalimumab levels [median 0.0\u00a0\u00b5g\/mL (IQR 0.0, 0.0) vs. 5.0\u00a0\u00b5g\/mL (IQR 2.8, 7.8),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002]. There was no association between ADA-A and the duration of adalimumab therapy, use of concurrent conventional immunosuppression, presence of systemic inflammatory disease, uveitis activity, visual acuity or adverse effects to adalimumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADA-A were uncommon, and their presence may be associated with obesity, increased C-reactive protein, and poorer patient-reported health. Within the limitations of our statistical power, the presence of ADA-A was not associated with systemic inflammatory disease, uveitis activity, nor adalimumab monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-025-00567-6","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T09:02:19Z","timestamp":1766653339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The prevalence and potential associations of anti-drug antibodies against adalimumab in patients with non-infectious uveitis: a cross-sectional study"],"prefix":"10.1186","volume":"16","author":[{"given":"Ashwin","family":"Madhavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian J.","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya D.","family":"Samalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndell L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"issue":"9","key":"567_CR1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","volume":"88","author":"OM Durrani","year":"2004","unstructured":"Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159\u20131162","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"567_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","volume":"134","author":"JE Thorne","year":"2016","unstructured":"Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J et al (2016) Prevalence of noninfectious uveitis in the united states: A Claims-Based analysis. JAMA Ophthalmol 134(11):1237\u20131245","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"567_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932\u2013943","journal-title":"N Engl J Med"},{"issue":"7","key":"567_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1084\/jem.20151255","volume":"213","author":"DX Nguyen","year":"2016","unstructured":"Nguyen DX, Ehrenstein MR (2016) Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF\u2013TNF-RII binding in rheumatoid arthritis. J Exp Med 213(7):1241\u20131253","journal-title":"J Exp Med"},{"issue":"4","key":"567_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T et al (2017) Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs 31(4):299\u2013316","journal-title":"BioDrugs"},{"issue":"14","key":"567_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during Long-term Follow-up. JAMA 305(14):1460\u20131468","journal-title":"JAMA"},{"issue":"4","key":"567_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/art.30209","volume":"63","author":"LA Korswagen","year":"2011","unstructured":"Korswagen LA, Bartelds GM, Krieckaert CLM, Turkstra F, Nurmohamed MT, van Schaardenburg D et al (2011) Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study. Arthr Rhuem 63(4):877\u2013883","journal-title":"Arthr Rhuem"},{"issue":"4","key":"567_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B et al (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune Diseases. A systematic review and Meta-Analysis. BioDrugs 29(4):241\u2013258","journal-title":"BioDrugs"},{"issue":"4","key":"567_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","volume":"37","author":"A Akihiko","year":"2010","unstructured":"Akihiko A, Nakagawa H, Etoh T, Ohtsuki M (2010) Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study. J Dermatol 37(4):299\u2013310","journal-title":"J Dermatol"},{"issue":"2","key":"567_CR10","first-page":"228","volume":"36","author":"G Bornstein","year":"2018","unstructured":"Bornstein G, Lidar M, Langevitz P, Fardman A, Ben-Zvi I, Grossman C (2018) The prevalence and clinical effect of immunogenicity of TNF-\u03b1 blockers in patients with axial spondyloarthritis. Clin Exp Rheumatol 36(2):228\u2013232","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"567_CR11","doi-asserted-by":"publisher","first-page":"e2323098","DOI":"10.1001\/jamanetworkopen.2023.23098","volume":"6","author":"S Bitoun","year":"2023","unstructured":"Bitoun S, H\u00e4ssler S, Ternant D, Szely N, Gleizes A, Richez C et al (2023) Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw Open 6(7):e2323098\u2013e","journal-title":"JAMA Netw Open"},{"issue":"3","key":"567_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/imt-2018-0081","volume":"11","author":"R Talotta","year":"2019","unstructured":"Talotta R, Rucci F, Canti G, Scaglione F (2019) Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Immunotherapy 11(3):241\u2013254","journal-title":"Immunotherapy"},{"issue":"6","key":"567_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00296-021-04955-8","volume":"42","author":"J Hiltunen","year":"2022","unstructured":"Hiltunen J, Parmanne P, Sokka T, Lamberg T, Isom\u00e4ki P, Kaipiainen-Sepp\u00e4nen O et al (2022) Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. Rheumatol Int 42(6):1015\u20131025","journal-title":"Rheumatol Int"},{"issue":"6","key":"567_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A et al (2014) Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with crohn\u2019s disease. Aliment Pharmacol Ther 40(6):620\u2013628","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"567_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","volume":"141","author":"S Bellur","year":"2023","unstructured":"Bellur S, McHarg M, Kongwattananon W, Vitale S, Sen HN, Kodati S (2023) Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis. JAMA Ophthalmol 141(2):150\u2013156","journal-title":"JAMA Ophthalmol"},{"key":"567_CR16","doi-asserted-by":"crossref","unstructured":"Berger AE, Gleizes A, Waeckel L, Roblin X, Krzysiek R, Hacein-Bey-Abina S et al (2022) Validation study of a new random-access chemiluminescence immunoassay analyzer i-TRACK10(\u00ae) to monitor infliximab and adalimumab serum trough levels and anti-drug antibodies. Int J Mol Sci. ;23(17)","DOI":"10.3390\/ijms23179561"},{"key":"567_CR17","doi-asserted-by":"crossref","unstructured":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. American Journal of Ophthalmology (2005) ;140(3):509\u2009\u2013\u200916","DOI":"10.1016\/j.ajo.2005.03.057"},{"issue":"1","key":"567_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12886-024-03447-0","volume":"24","author":"U Tungsattayathitthan","year":"2024","unstructured":"Tungsattayathitthan U, Jenjanya S, Choopong P, Sanphan W, Tesavibul N, Boonsopon S (2024) Prevalence, clinical characteristics, and independent predictors of uveitic macular edema in an Asian population: a retrospective cohort study. BMC Ophthalmol 24(1):181","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"567_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-item National eye Institute visual function questionnaire. Arch Ophthalmol 119(7):1050\u20131058","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"567_CR20","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s11136-013-0412-y","volume":"22","author":"RK Naik","year":"2013","unstructured":"Naik RK, Gries KS, Rentz AM, Kowalski JW, Revicki DA (2013) Psychometric evaluation of the National eye Institute visual function questionnaire and visual function questionnaire utility index in patients with non-infectious intermediate and posterior uveitis. Qual Life Res 22(10):2801\u20132808","journal-title":"Qual Life Res"},{"issue":"5","key":"567_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1183\/09031936.00110209","volume":"34","author":"EF Juniper","year":"2009","unstructured":"Juniper EF (2009) Validated questionnaires should not be modified. Eur Respir J 34(5):1015\u20131017","journal-title":"Eur Respir J"},{"key":"567_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ (2018) Role of C-Reactive protein at sites of inflammation and infection. Front Immunol 9:754","journal-title":"Front Immunol"},{"key":"567_CR23","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Nogueras VS, Hidalgoa LM, Jim\u00e9nez Rodr\u00edguez E, Garc\u00eda Basterra I, Rivera de Zea P, Alba Linero C (2018) Influence of immunogenicity of adalimumab on prognosis of patients with non-infectious-uveitis: a systematic review. Ocul Immunol Inflamm 33(10):2307\u20132316","DOI":"10.1080\/09273948.2025.2486371"},{"key":"567_CR24","doi-asserted-by":"crossref","unstructured":"Pach\u00f3n-Su\u00e1rez DI, Z\u00e1rate-Pinz\u00f3n L, Cifuentes-Gonz\u00e1lez C, Rojas-Carabali W, Mej\u00eda-Salgado G, Pineda JS et al (2024) Immunogenicity of adalimumab in patients with non-infectious- uveitis: systematic review and meta-analysis. Ocul Immunol Inflamm 32(8):1539\u20131548","DOI":"10.1080\/09273948.2023.2256850"},{"issue":"12","key":"567_CR25","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","volume":"123","author":"M Cordero-Coma","year":"2016","unstructured":"Cordero-Coma M, Calleja-Antol\u00edn S, Garzo-Garc\u00eda I, Nu\u00f1ez-Garn\u00e9s AM, \u00c1lvarez-Castro C, Franco-Benito M et al (2016) Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology 123(12):2618\u20132625","journal-title":"Ophthalmology"},{"issue":"22","key":"567_CR26","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","volume":"282","author":"M Visser","year":"1999","unstructured":"Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282(22):2131\u20132135","journal-title":"JAMA"},{"issue":"5","key":"567_CR27","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ et al (2018) Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE 13(5):e0195123","journal-title":"PLoS ONE"},{"issue":"2","key":"567_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","volume":"36","author":"M Bassi","year":"2022","unstructured":"Bassi M, Singh S (2022) Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases. Biodrugs 36(2):197\u2013203","journal-title":"Biodrugs"},{"key":"567_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ajo.2024.12.009","volume":"271","author":"F Pichi","year":"2025","unstructured":"Pichi F, AlAli SH, Jimenez YP, Neri P (2025) High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis. Am J Ophthalmol 271:381\u2013388","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"567_CR30","doi-asserted-by":"publisher","first-page":"e061476","DOI":"10.1136\/bmjopen-2022-061476","volume":"12","author":"S Kulkarni","year":"2022","unstructured":"Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S et al (2022) Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open 12(12):e061476","journal-title":"BMJ Open"},{"issue":"6","key":"567_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/FTD.0000000000000795","volume":"42","author":"MJ Sam","year":"2020","unstructured":"Sam MJ, Connor SJ, Ng WW, Toong CM (2020) Comparative evaluation of 4 commercially available ELISA kits for measuring adalimumab and Anti-adalimumab antibodies. Ther Drug Monit 42(6):821\u2013828","journal-title":"Ther Drug Monit"},{"key":"567_CR32","doi-asserted-by":"crossref","unstructured":"Kharlamova N, Hermanrud C, Dunn N, Ryner M, Hambardzumyan K, Vivar Pomiano N et al (2020) Drug tolerant anti-drug antibody assay for infliximab treatment in clinical practice identifies positive cases earlier. Front Immunol. 11","DOI":"10.3389\/fimmu.2020.01365"},{"key":"567_CR33","doi-asserted-by":"crossref","unstructured":"P\u0119kala A, Filip R, Aebisher D (2021) Anti-Drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: a prospective cohort study. J Clin Med. 10(12)","DOI":"10.3390\/jcm10122653"},{"key":"567_CR34","unstructured":"Theradiag (2021) i-Tracker anti-Adalimumab. In: Theradiag, editor"},{"issue":"7","key":"567_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/MIB.0000000000001100","volume":"23","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD et al (2017) Effects of transient and persistent Anti-drug antibodies to certolizumab pegol: longitudinal data from a 7-Year study in crohn\u2019s disease. Inflamm Bowel Dis 23(7):1047\u20131056","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"567_CR36","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, D\u2019Haens G, Rutgeerts P (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to Infliximab in crohn\u2019s disease. Gut 56(9):1226\u20131231","journal-title":"Gut"},{"issue":"6","key":"567_CR37","first-page":"1043","volume":"35","author":"ST Leinonen","year":"2017","unstructured":"Leinonen ST, Aalto K, Kotaniemi KM, Kivel\u00e4 TT (2017) Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol 35(6):1043\u20131046","journal-title":"Clin Exp Rheumatol"},{"key":"567_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","volume":"240","author":"LEM Eurelings","year":"2022","unstructured":"Eurelings LEM, Missotten T, van Velthoven MEJ, van Daele PLA, van Laar JAM, van Hagen PM et al (2022) Long-Term Follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy. Am J Ophthalmol 240:194\u2013204","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"567_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevImmunol.2025057969","volume":"45","author":"VD Nimbarte","year":"2025","unstructured":"Nimbarte VD, Sonak SS, Ishwarkar S (2025) Understanding the impact of calcineurin inhibitors on T cell regulation: mechanisms and clinical implications. Crit Rev Immunol 45(4):43\u201356","journal-title":"Crit Rev Immunol"},{"key":"567_CR40","doi-asserted-by":"publisher","unstructured":"Preglej T, Tosevska A, Brinkmann M, Schatzlmaier P, Simader E, Sieghart D et al (2025) Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy (pre-print). BioRxiv. https:\/\/doi.org\/10.1101\/2025.01.14.629357","DOI":"10.1101\/2025.01.14.629357"},{"key":"567_CR41","volume-title":"Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis","author":"AJ Bromeo","year":"2023","unstructured":"Bromeo AJ (2023) Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis. ARVO, New Orleans"},{"key":"567_CR42","unstructured":"Rubin DT (2019) Restarting biologic agents after a drug holiday. Gastroenterol hepatol (N Y) 15(11):612\u2013615"},{"issue":"3","key":"567_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/joim.13495","volume":"292","author":"MK Brun","year":"2022","unstructured":"Brun MK, Goll GL, J\u00f8rgensen KK, Sexton J, Gehin JE, Sandanger \u00d8 et al (2022) Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med 292(3):477\u2013491","journal-title":"J Intern Med"},{"key":"567_CR44","doi-asserted-by":"crossref","unstructured":"Lu X, Hu R, Peng L, Liu M, Sun Z (2021) Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. Front Immunol. ;12","DOI":"10.3389\/fimmu.2021.638444"},{"issue":"1","key":"567_CR45","doi-asserted-by":"publisher","first-page":"e000987","DOI":"10.1136\/rmdopen-2019-000987","volume":"6","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Kellner H, Arai Y, Muniz R, Alten R (2020) Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open 6(1):e000987","journal-title":"RMD Open"},{"issue":"6","key":"567_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archopht.119.6.841","volume":"119","author":"RM Schiffman","year":"2001","unstructured":"Schiffman RM, Jacobsen G, Whitcup SM (2001) Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 119(6):841\u2013849","journal-title":"Arch Ophthalmol"},{"key":"567_CR47","doi-asserted-by":"publisher","first-page":"104754","DOI":"10.1016\/j.compbiomed.2021.104754","volume":"136","author":"M Safaei","year":"2021","unstructured":"Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi\u2019i A (2021) A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med 136:104754","journal-title":"Comput Biol Med"},{"key":"567_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-48382-5_1","volume":"960","author":"A Engin","year":"2017","unstructured":"Engin A (2017) The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol 960:1\u201317","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"567_CR49","doi-asserted-by":"publisher","first-page":"e0175207","DOI":"10.1371\/journal.pone.0175207","volume":"12","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH et al (2017) The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE 12(4):e0175207","journal-title":"PLoS ONE"},{"issue":"3","key":"567_CR50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J (2019) Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child 104(3):246\u2013250","journal-title":"Arch Dis Child"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00567-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00567-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00567-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:47:15Z","timestamp":1781624835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-025-00567-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["567"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00567-6","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Royal Victorian Eye and Ear Hospital Human Research Ethics Committee (reference number 22\/1557HL) and was conducted in adherence with the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for participation in the study was obtained from all participants. This manuscript does not contain any individual person\u2019s details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM: No competing interests; SLR: No competing interests; JJB: No competing interests; LR: Grant funding from Australian Rheumatology Association, University of Melbourne, SCTC Working Group; PDS: No competing interests; AJH: Advisory board (AbbVie), Consulting fees (Roche, Novartis and UCB); LLL: Grants (Bayer, Roche), Consultant (Bayer, Roche, Novotech), Payment\/honoraria (Roche, Novartis, Bayer), Executive Board Member of International Ocular Inflammation Society (unpaid).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}